VLX103

Developed for: fatty liver disease
Investigated by: Gyongyi Szabo · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · The Cleveland Clinic · University of Louisville · University of Texas Southwestern Medical Center

today NCT03201159 · Ph 1

2018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT03201159	Jun 2017 → Feb 2018	fatty liver disease	Gyongyi Szabo	Withdrawn	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	VLX103	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03201159 ↗
Route	Oral	“administered by mouth as an oral tablet” NCT03201159 ↗